Drug class
Selective orexin receptor 2 (OX2R) agonist; wake-promoting agent
Mechanism of action
Directly activates orexin type 2 receptors (OX2R), restoring orexin signalling that is deficient in narcolepsy type 1. OX2R activation promotes wakefulness and supports regulation of sleep-wake states and cataplexy-related pathways.
General use cases
- Treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults under the US ORZEYFUL product label (FDA approval August 5, 2026).
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
